Evidence map›Paper›PMID 29063487›Full record

Trial reportInflammopharmacology2018

Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis.

Hossein Ahmadi, Mahdi Mahmoudi, Farhad Gharibdoost, Mahdi Vojdanian, Ahmad Reza Jamshidi, Mohammad Javad Fattahi, Zahra Aghazadeh, Anis Barati, Abbas Mirshafiey

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Inflammopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hossein AhmadiDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.
Mahdi MahmoudiRheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Farhad GharibdoostRheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mahdi VojdanianRheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ahmad Reza JamshidiRheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Javad FattahiDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.
Zahra AghazadehDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.
Anis BaratiDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.
Abbas MirshafieyDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran. mirshafiey@tums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed at investigating the inhibitory effect of β-D-mannuronic acid (M2000) on the Th17 circulating levels and IL-17 a related cytokine in rheumatoid arthritis (RA) patients.

methodsThe study included 27 patients with RA who had failed response to treatment. All patients were treated orally by M2000 at a dose of 500 mg twice daily for 12 weeks (Clinical trial identifier: IRCT2014011213739N2). The patients based on anti-tumor necrosis factor alpha (TNFα) blocker treatment were classified into two groups (conventional group and etanercept group). They were then allowed to continue their treatment excluding non-steroidal anti-inflammatory drugs (NSAIDs). The frequency of circulating Th17 cells and IL-17 serum level were determined before and 12 weeks after M2000 therapy and were compared to the healthy controls by using flow cytometry analysis and ELISA method, respectively.

resultsAt baseline, higher circulating Th17 and IL-17 serum levels were significantly observed in both groups of RA patients than in the healthy controls (all P < 0.001). The frequency of Th17 cells significantly decreased in the conventional group as well as in the etanercept group after M2000 therapy but the level of reduction was higher in the conventional group compared to the etanercept group (P < 0.03 and P < 0.04, respectively). The IL-17 serum level significantly decreased in both groups after M2000 therapy (P < 0.01 and P < 0.02, respectively). Furthermore, the frequency of Th17 cells was positively correlated with Disease Activity Score (DAS28) (r = 0.34, P = 0.02).

conclusionM2000 shows the inhibitory effect on the frequency of circulating Th17 cells as well as in the production of IL-17 in RA patients.

Indexed as

AdultAgedAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, RheumatoidCase-Control StudiesCytokinesEtanerceptFemaleHexuronic AcidsHumansInterleukin-17MaleMiddle AgedTh17 CellsTumor Necrosis Factor-alphaAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsCytokinesEtanerceptHexuronic AcidsInterleukin-17mannuronic acidTumor Necrosis Factor-alphaDMARDIL-17M2000Mannuronic acidRheumatoid arthritisTh17 cells

Identifiers

PMID29063487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.